Urology Research & Practice
NEUROUROLOGY - Original Article

Evaluation of progression from first to second stage sacral neuromodulation and unplanned device removal


Department of Urology, Loma Linda University, Loma Linda, CA, USA

Urol Res Pract 2021; 47: 58-65
DOI: 10.5152/tud.2020.20288
Read: 543 Downloads: 209 Published: 01 January 2021

Objective: Sacral neuromodulation (SNM) is an advanced treatment option for patients with refractory overactive bladder (OAB) symptoms, urinary retention, and bowel disorders; it is usually performed in 2 separate procedures. This study aims to determine a cohort’s progression rate from stage 1 to 2 and predict factors for progression and unplanned device removal or revision.

Material and methods: A retrospective review was conducted in patients who underwent SNM at a single institution between June 2012 and May 2019. Progression rates from stage 1 to 2, patient characteristics, and indications for unplanned SNM removal or revision were recorded. Chi-square, Mann-Whitney U, and Fisher’s exact tests were used for data analysis.

Results: A total of 128 patients underwent SNM for 1 or more of the following diagnoses: OAB (n=103), urinary retention (n=15), neurogenic bladder dysfunction (n=4), fecal incontinence (n=2), and constipation (n=4). The progression rate to stage 2 was 92.2% (118/128). Patients who failed to progress to stage 2 had additional diagnoses other than OAB, such as urinary retention or bowel disorders (p=0.007). Fifteen patients (12.7%) required SNM removal or revision within 4 years of surgery. Among these patients, the body mass index was significantly lower (p=0.036).

Conclusion: Most patients (92.2%) progressed to stage 2. Patients with only OAB symptoms had a higher progression rate to stage 2. Single full-stage procedures may be considered in select patients to reduce morbidity, time, and costs.

Cite this article as: Feldkamp A, Amasyalı AS, Groegler J, Jellison F, Staack A. Evaluation of progression from first to second stage sacral neuromodulation and unplanned device removal. Turk J Urol 2021; 47(1): 58-65.

EISSN 2980-1478